Ecuador IVD Classification Rules: DMDIV Entry Caps, Grouping and Labeling Requirements

1. Key takeaways

In the new regulation, in vitro diagnostic medical devices appear as a distinct device type, DMDIV, subject to three special rules that differ from those for devices: the per-application entry cap is 50 entries (versus 100 for devices); combining models under one certificate requires both the same analytical methodology and the same analyte group to be investigated; and the instructions for use must contain 12 elements including the principle of the methodology, performance characteristics and limitations. IVD portfolios therefore need their own grouping architecture instead of a copy of the device logic.

2. Legal basis

3. Expert insights

Insight 1: the difference in combining conditions between DMDIV and devices is the watershed of dossier assembly. Devices are grouped by five shared attributes (type, class, product owner, manufacturer, intended use), while DMDIVs require the same risk class plus analytical methodology plus analyte group plus manufacturer plus intended use plus product owner. Analytical methodology and analyte group are dimensions unique to IVDs: reagents from the same manufacturer and in the same risk class but using different methodologies cannot be combined under one certificate. This forces IVD families into more, smaller certificates than an equivalent device portfolio would require.

Insight 2: ARCSA will issue separate instructions determining grouping and methodology, which is the current filing uncertainty. The final paragraph of Article 14(2) states: ARCSA will issue the corresponding instructions establishing the grouping and the analytical methodologies of in vitro diagnostic medical devices for human use. This means the boundary of IVD combined certification remains pending verification, and early filings should adopt conservative grouping (splitting strictly by methodology). Once the instructions are published, groupings can be optimized through variation applications.

Insight 3: Article 52 lists a more detailed element inventory for IVD instructions than for devices. IVD instructions for use must contain at least: trade name; application and use; components and kit contents; methodology; principle of the method; performance standards and limitations of the method; reagent preparation; reagent storage conditions and stability; specimen or sample; procedure steps; internal quality control; and reference intervals where applicable, 12 items in total. Among them, performance standards and limitations of the method correspond directly to the performance study documentation required by Article 24(2.4), so the two workstreams should be drafted consistently.

Insight 4: there are two terminology points that are easy to confuse. Article 3 defines both RDIV (Reactivo para Diagnóstico in vitro, in vitro diagnostic reagent) and DMDIV (Dispositivo Médico de Diagnóstico in vitro, in vitro diagnostic medical device). DMDIV is the device type for registration purposes, while RDIV refers to the reagent itself; dossier assembly should use DMDIV consistently. Mixing the two abbreviations in a filing invites completeness queries and inconsistent references across the technical documentation.

Insight 5: the Article 24 technical documentation matrix has a dedicated row for DMDIV and distinguishes reagents from instruments. For example, the description of raw or source materials applies to all risk classes of DMNI, DMI and DMDIV; the description of primary and secondary packaging applies to DMDIV products of all classes that are not electrical medical equipment or laboratory equipment; and the IEC certificates under item 2.7 apply to DMA and DMDIV products regarded as electrical medical equipment or laboratory equipment. Instruments and reagents within the IVD family are thus treated differently in technical documentation requirements. A single template for all IVDs will inevitably leave gaps for one of the two groups.

4. Practical recommendations

1. Split IVD applications strictly by methodology plus analyte group, and optimize combinations only after the ARCSA instructions are issued.
2. Draft the instructions item by item against the 12 elements of Article 52(2), with priority on performance standards and method limitations.
3. Use the DMDIV and RDIV terms correctly: registration documents should uniformly use DMDIV.
4. Plan IVD families in batches under the 50-entry cap, expanding through variation applications where needed.
5. Check the Article 24 matrix separately for instrument-type and reagent-type IVDs instead of applying a uniform template.

5. Verification checklist

• □ Completed IVD model grouping by methodology plus analyte group
• □ Checked the entry cap of 50 entries for DMDIV
• □ Instructions for use cover the 12 elements of Article 52(2)
• □ Unified use of the DMDIV term (not RDIV)
• □ Checked the Article 24 matrix separately for instrument-type and reagent-type IVDs
• □ Set up tracking of the ARCSA instructions on methodology and grouping

Regulatory information verified as of October 29, 2026

Core service areas

1. Global market access: EU CE (MDR/IVDR), US FDA (510(k)/De Novo/PMA), UK UKCA, Australia TGA, Canada Health Canada, Brazil ANVISA and Russia RZN, plus premarket registration pathway planning and filing execution across Latin America, Southeast Asia, the Middle East and other markets.
2. Authorized representative services: EU authorized representative (EC REP), UK responsible person (UK RP), Swiss authorized representative (CH REP), Australia sponsor and US Agent, together with neutral certificate-holder structure design.
3. Quality system compliance: ISO 13485 implementation and maintenance, MDSAP audit preparation, GMP conformity coaching, and technical documentation (TD) authoring and remediation.
4. Clinical and evaluation: clinical evaluation plans (CEP) and reports (CER), equivalence argumentation, PMCF planning and execution, and IVD performance evaluation.
5. Post-market compliance: vigilance and adverse event reporting, FSCA and recall execution, registration change and renewal management, and maintenance of national regulatory databases.

Why GRZAN

• Local regulatory teams: filings in each target market are executed by locally licensed regulatory professionals and prepared directly in the official language of the market, without secondary translation.
• Neutral holding structure: certificate-holding arrangements that are not tied to any distribution channel, keeping registrations independent of channel partners.
• Regional leverage: a single technical dossier can be reused across Andean Community and Mercosur member states, spreading regional compliance cost.
• Full lifecycle support: end-to-end service from classification, pathway design and dossier preparation through certificate holding, customs clearance, post-market vigilance and renewal.

Contact

• GRZAN provides medical device registration support in Ecuador for manufacturers, importers and authorized representatives.
• Email: info@grzanglobal.com
• Service inquiries: Ecuador and Andean market registration plans, certificate-holding structure design, official fee and timeline estimation